Уровни MCP-1, IL-6 и генов CCL2, IL6 у мужчин с нестабильными атеросклеротическими бляшками

1. Abraham G., Havulinna A. OB-E heart, 2016 U. Genomic prediction of coronary heart disease. academic.oup. com. Accessed April 27, 2020. https://academic.oup.com/eurheartj/article-abstract/37/43/3267/2658448

2. de Vries M.A., Trompet S., Mooijaart S.P., et al. Complement receptor 1 gene polymorphisms are associated with cardiovascular risk. Atherosclerosis, 2017; 257: 16–21. doi: 10.1016/j.atherosclerosis.2016.12.017

3. Waksman Ron, Patrick W. Serruys, Schaar J. Handbook of the Vulnerable Plaque. 2nd ed. CRC Press; 2007. Accessed July 13, 2020. https://www.amazon.com/Handbook-Vulnerable-Plaque-Ron-Waksman/dp/184184621X

4. Charo I.F., Taubman M.B. Chemokines in the pathogenesis of vascular disease. Circ. Res., 2004; 95 (9): 858–866. doi: 10.1161/01.RES.0000146672.10582.17

5. Lin J., Kakkar V., Lu X. Impact of MCP-1 in Atherosclerosis. Curr. Pharm. Des., 2014; 20 (28): 4580–4588. doi: 10.2174/1381612820666140522115801

6. Reference SNP (refSNP) Cluster Report: rs1024611 ** With Pathogenic allele **. Accessed September 8, 2020. https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?do_not_redirect&rs=rs1024611

7. Rovin B.H., Lu L., Saxena R. A novel polymorphism in the MCP-1 gene regulatory region that influences MCP-1 expression. Biochem. Biophys. Res. Commun., 1999; 259 (2): 344–348. doi: 10.1006/bbrc.1999.0796

8. Cai G., Zhang B., Weng W., Shi G., Huang Z. The associations between the MCP-1 –2518 A/G polymorphism and ischemic heart disease and ischemic stroke: A meta-analysis of 28 research studies involving 21,524 individuals. Mol. Biol. Rep., 2015; 42 (5): 997–1012. doi: 10.1007/s11033-014-3836-8

9. Schuett H., Luchtefeld M., Grothusen C., Grote K., Schieffer B. How much is too much? Interleukin-6 and its signalling in atherosclerosis. Thrombosis and Haemostasis, 2009; 102: 215–222. doi: 10.1160/TH09-05-0297

10. Hartman J., Frishman W.H. Inflammation and atherosclerosis: A review of the role of interleukin-6 in the development of atherosclerosis and the potential for targeted drug therapy. Cardiol. Rev., 2014; 22 (3): 147–151. doi: 10.1097/CRD.0000000000000021

11. Reference SNP (refSNP) Cluster Report: rs1800795 **Clinical Channel**. Accessed September 8, 2020. https://www.ncbi.nlm.nih.gov/projects/SNP/ snp_ref.cgi?do_not_redirect&rs=rs 1800795

12. Li Y.Y., Zhou C.W., Xu J., Qian Y., Wang X.M. Interleukin-6 C-572G gene polymorphism and coronary artery disease in asian: A meta-analysis of 2511 subjects. Int. J. Clin. Exp. Med., 2015; 8 (6): 8995–9003. Accessed September 8, 2020. https://pubmed.ncbi.nlm.nih.gov/26309552/

13. Rizzello V., Liuzzo G., Trabetti E., et al. Role of the CD14 C(-260)T promoter polymorphism in determining the first clinical manifestation of coronary artery disease. J. Cardiovasc. Med., 2010; 11 (1): 20–25. doi: 10.2459/JCM.0b013e328330e9fb

14. Dietel B., Cicha I., Voskens C.J., Verhoeven E., Achenbach S., Garlichs C.D. Decreased numbers of regulatory T cells are associated with human atherosclerotic lesion vulnerability and inversely correlate with infiltrated mature dendritic cells. Atherosclerosis, 2013; 230 (1): 92–99. doi: 10.1016/j.atherosclerosis. 2013.06.014

15. Niu W., Liu Y., Qi Y., et al. Association of interleukin-6 circulating levels with coronary artery disease: a meta-analysis implementing mendelian randomization approach. Elsevier. Accessed April 27, 2020. https://www.sciencedirect.com/science/article/pii/S0167527311022790